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Abstract 25 
Traumatic brain injury (TBI) is a neurological condition which affects a large number of individuals 26 
worldwide, across all ages. It can lead to major physical, cognitive and psychological impairment, and 27 
represents a considerable health cost burden. TBI is a heterogeneous condition and there has been 28 
intense effort over the last decade to identify better biomarkers, which would enable an optimum and 29 
personalized treatment. The brain is highly enriched in a variety of lipids, including fatty acids, 30 
glycerophospholipids, glycerolipids, sterols and sphingolipids. There is accumulating evidence in 31 
clinical studies in TBI patients and also in experimental models of TBI, that injury triggers a complex 32 
pattern of changes in various lipid classes. Such changes can be detected in blood (plasma/serum), 33 
cerebrospinal fluid and also in brain tissue. They provide new insights into the pathophysiology of TBI, 34 
and have biomarker potential. Here, we review the various changes reported and discuss the scope 35 
and value of these lipid focused studies within the TBI field. 36 
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1 Abbreviations: 
ApoE: Apolipoprotein E 
ARA: Arachidonic acid (20:4n-6) 
BBB: Blood-brain barrier 
CCI: Controlled cortical impact 
CNS: Central nervous system 
CSF: Cerebrospinal fluid 
CT: Computer tomography 
DHA: Docosahexaenoic acid (22:6n-3) 
GCS: Glasgow Coma Scale 
LysoPL: Lysophospholipid(s) 
MRI: Magnetic resonance imaging 
PC: Phosphatidylcholine 
PE: Phosphatidylethanolamine 
PGE2: Prostaglandin E2 
PI: Phosphatidylinositol 
PL: Phospholipid(s) 
PLA2: Phospholipase A2 
PND: Postnatal day  
PS: Phosphatidylserine 
SM: Sphingomyelin 
TBI: Traumatic brain injury 
1. Introduction 41 
Traumatic brain injury (TBI) is a major health problem worldwide and is associated with a significant 42 
socioeconomic burden [1, 2]. It is a neurological condition which can lead to life-changing physical, 43 
psychological and cognitive changes [3, 4]. There is also accumulating evidence that TBI significantly 44 
increases the risk of developing neurodegenerative disease, such as dementia [5-8]. TBI is a major 45 
cause of death and disability below 45 years of age in Western countries [9], and the growing number 46 
of TBI cases, including an increased prevalence in the elderly, highlights the need to develop sensitive 47 
TBI diagnostic and prognostic tools, and improved treatment. TBI can occur in a variety of contexts 48 
(e.g. traffic accidents, falls, assaults and military combat). It is a very heterogeneous condition, and 49 
the considerable variation between patients implies a significant need for personalized management. 50 
Collaborative efforts worldwide, such as the CENTER-TBI and Transforming Research and Clinical 51 
Knowledge in TBI (TRACK-TBI) initiatives, have been addressing the need for the acquisition of 52 
comprehensive datasets, and the development of complex outcome assessment batteries, which 53 
could ultimately lead to improved effectiveness in neurotrauma [10, 11].  54 
The severity of TBI is graded neurologically using the Glasgow Coma Scale (GCS), based on motor, eye 55 
and verbal responses which evaluate the patient’s level of consciousness. However, the GCS has 56 
limited clinical value and is unsatisfactory [12]. Additional information can be obtained through 57 
imaging methods such as magnetic resonance imaging (MRI) and computer tomography (CT), which 58 
provide more objective information on the magnitude and localization of the injury [13]. However, CT 59 
scans lack sensitivity in mild to moderate diffuse brain injury, and the availability and feasibility of MRI 60 
limits its broad clinical use. It is worth underlining that, in this type of injury, advanced neuroimaging 61 
techniques, such as diffusion tensor imaging (DTI), magnetic resonance spectroscopy (MRS) and 62 
functional MRI (fMRI) provide useful objective information of diagnostic and prognostic value [14-17]. 63 
Therefore, there is a need for additional biomarkers for TBI, with high specificity and sensitivity [18], 64 
which would enable a refinement of diagnosis and prognosis of outcome. This need has led to a 65 
sustained effort over the last decade to identify various types of biomarkers of TBI in blood [19-21]. 66 
Among these biomarkers there is a very limited representation of lipids, although the brain is the 67 
organ which is most enriched in lipids, that represent more than 60% of its dry weight. 68 
Lipids are a major class of cellular components, which show a wide diversity. They have a variety of 69 
structural and signalling roles, and a key role in energy storage and supply. The developments in 70 
biochemical analysis, instrumentation and bioinformatics have led to the development of lipidomics, 71 
i.e. the study of lipid classes, lipid networks and pathways, and have allowed insights into the 72 
complexity of lipid profiles and their dynamics during development, in aging and in disease states. The 73 
efforts of the LIPID MAPS consortium have led to a classification of lipids, which is regularly updated, 74 
and also a standardization of protocols and an improved availability of high-quality standards 75 
(http://www.lipidmaps.org). Lipids are grouped under the following major categories: fatty acyls, 76 
glycerolipids, glycerophospholipids, sphingolipids, sterol lipids, prenol lipids, saccharolipids and 77 
polyketides [22]. Methods based on mass spectrometry have enabled the qualitative and quantitative 78 
analysis of lipids in complex tissue matrices, either in a targeted or untargeted mode [23]. Reference 79 
material for specific tissues has become available, e.g. Quehenberger and collaborators [24] have 80 
published an analysis of plasma lipids in a human plasma standard reference material. This material 81 
was prepared by obtaining plasma samples from 100 individuals between 40 and 50 years of age, 82 
ethnically representative of the US population, including an equal number of men and women.  83 
The central nervous system (CNS) contains thousands of different lipid species and most brain lipids 84 
are synthesized locally and are separated from the peripheral compartment by the blood-brain barrier 85 
(BBB) [25]. Using an untargeted lipidomic approach, Bozek et al. [26] carried out a comprehensive 86 
brain lipidome analysis in several species: human, chimpanzee, macaque and mouse. Their analysis 87 
showed that in humans, in evolutionary terms, there is an increased brain lipid specificity as shown by 88 
comparison to the kidney or muscle lipidome, with striking differences in this specificity seen even 89 
between chimpanzees and humans, who have a high degree of genetic relatedness. Between brain 90 
regions (considering the prefrontal cortex, the primary visual area and the cerebellum), there were 91 
also lipid differences. Interestingly, there was a 3-fold acceleration of lipid specialization and 92 
divergence in the neocortex vs. the cerebellum. Therefore, there was greater lipidome divergence 93 
between the brain and non-neural tissues in species that show greater cognitive complexity, and a 94 
faster divergence of lipids enriched in brain compared with lipids enriched in non-neural tissues. These 95 
observations suggest a link between the evolution of the brain lipidome and the evolution of brain 96 
functionality and its increasing complexity on the phylogenetic scale. This supports the idea that lipids 97 
fulfil unique roles in the CNS. 98 
TBI disrupts tissue architecture and leads to complex alterations in all tissue components, including 99 
lipids. Measurable and minimally invasive biomarkers which are reliable indicators of the CNS injury 100 
and predict the evolution and outcome, are pivotal tools for optimized therapeutic management. 101 
Changes in lipids which can be detected peripherally (blood, plasma or serum) have been increasingly 102 
reported after TBI. The aim of this review is to summarize findings of alterations in lipids following TBI 103 
in humans and also in experimental models of TBI, in both the peripheral compartment (blood, plasma, 104 
serum) and central compartment (brain tissue, cerebral microdialysate and cerebrospinal fluid (CSF)), 105 
in order to identify a potential lipid signature of TBI which may have unique value in the growing 106 
armamentarium of biomarkers for this condition. The CNS is enriched in specific lipids, i.e. fatty acids, 107 
phospholipids (PL), sphingolipids, glycerolipids and sterols, with complex structural and signalling roles 108 
[25, 27]. These species are the major lipids in the studies discussed here, and they are briefly reviewed 109 
below. Their general structures are shown in Figure 1 [28]. 110 
 111 
Figure 1: Examples of lipid species structures from the main classes of lipids (LIPID MAPS; 112 
https://www.lipidmaps.org/) 113 
 114 
Fatty acids are essential building blocks of more complex lipids. They have varying chain lengths and 115 
can be saturated (e.g. palmitic acid, 16:0), monounsaturated (e.g. oleic acid 18:1n-9) or 116 
polyunsaturated (e.g. α-linolenic acid, 18:3n-3). Polyunsaturated fatty acids such as arachidonic acid 117 
(ARA, 20:4n-6) or docosahexaenoic acid (DHA, 22:6n-3), have structural and signalling roles, can 118 
activate a variety of receptors and can also give rise to a large array of lipid mediators, such as the 119 
ARA-derived eicosanoids and the DHA-related docosanoids [29, 30]. Phospholipids (or 120 
glycerophospholipids) are integral components of cell membranes and are by far the most abundant 121 
lipid species in the brain (45% of the dry weight). They have a glycerol backbone whose hydroxyl 122 
groups in the sn-1 and sn-2 positions are linked to fatty acids, whereas the polar phosphodiester group 123 
is linked to the sn-3 carbon. The esterified acyl residues can be saturated (e.g. palmitic acid or stearic 124 
acid) or unsaturated, the latter ranging from monounsaturated fatty acids (e.g. oleic acid) to 125 
polyunsaturated fatty acids (e.g. ARA or DHA). In general, PL have in sn-1 a saturated fatty acyl residue, 126 
and in sn-2 an unsaturated fatty acyl residue. Major PL species in cell membranes, based on the 127 
different polar group at sn-3, include phosphatidylcholine (PC), phosphatidylethanolamine (PE), 128 
phosphatidylserine (PS) and phosphatidylinositol (PI). In mammalian cells, the distribution of PL differs 129 
between the outer vs. the inner leaflet of the membrane lipid bilayer: the outer leaflet contains mainly 130 
PC, whereas PS and PE are found in the inner leaflet [31]. There is also a difference in the lipid 131 
composition between grey and white matter, as reported in humans [32]. PE is the most abundant in 132 
grey matter (30.7%), followed by PC (25.1%), cholesterol (19.6%), PS (7.2%), PI (3.9%), and 133 
sphingomyelin (SM) (3.2%). In white matter, cholesterol dominates (26.9%), followed by PE (19.6%), 134 
PC (11.8%), PS (9%), SM (4.4%), and PI (4%). Modulation of PL composition is essential for maintaining 135 
cellular and subcellular structures and for creating distinct lipid microdomains within membranes. The 136 
hydrolysis of PL by phospholipases, which cleave acyl residues in sn-1 or sn-2, produces 137 
lysophospholipids (lysoPL), which can act as intrinsic regulators of various biological processes [33]; 138 
for example, specific lysoPL species such as lysoPC, can have pro-inflammatory effects in nervous 139 
tissue [34, 35]. Sphingolipids are derived from the amino-alcohol sphingosine and include ceramides, 140 
phosphosphingolipids, such as SM, and glycosphingolipids. SM is distinct from glycerol-containing PL, 141 
as it is composed of mostly long saturated fatty acid chains. Glycerolipids are mono-, di- or tri- 142 
substituted glycerols, i.e. they have a glycerol backbone linked to a variable number of fatty acyl 143 
residues. Diacylglycerols can be a source of neuroactive endocannabinoids, such as 2-144 
arachidonoylglycerol, and the disruption of this biosynthetic pathway affects neurogenesis and 145 
synaptic plasticity [36]. Sterols are also important components of membrane lipids; cholesterol, a 146 
major sterol in mammals, is highly enriched in the brain, which contains about 20% of the body 147 
cholesterol [37]. It is essential for normal neural development, a precursor of neurosteroids such as 148 
dehydroepiandrosterone and allopregnanolone, and like SM, it is a major constituent of myelin. 149 
Cardiolipins are glycerophospholipids which are essential for the structure and function of 150 
mitochondria, where they accumulate in the inner membrane [38]. Cardiolipins contain a glycerol 151 
backbone and two phosphatidylglycerols, with four fatty acid chains [39]. Compared to other PL, 152 
cardiolipins are present in cells in low abundance [39]. There is a large number of cardiolipins in the 153 
brain, with longer chain fatty acids which are more unsaturated [38]. Using gas cluster ion beam 154 
secondary ion mass spectrometry, regional specific variations have been reported in the brain, with 155 
more unsaturated species with longer carbon chains localised in the cortical regions and cardiolipins 156 
with shorter chains and fewer double bonds in the hippocampus [39]. Comparison of human brain and 157 
heart cardiolipins revealed 26 brain specific cardiolipin species [40]. The distinct brain cardiolipin 158 
profile has also been confirmed in rats [40].  159 
2. Pathophysiology of TBI 160 
TBI may be penetrating or non-penetrating, focal or diffuse, and can be accompanied by concomitant 161 
traumatic injury to other parts of the body. It is an event resulting from the absorption by the brain of 162 
part of the energy associated with an external mechanical force (linear, rotational, and translational), 163 
not necessarily acting directly on the head, and causing acceleration/deceleration of the cerebral 164 
tissue. The energy associated with blast waves is also capable of producing head injuries similar to 165 
those occurring when a mechanical force is acting. These different types of forces can be mimicked 166 
experimentally in animals (mostly rodents), in models such as: the controlled cortical impact (CCI), the 167 
fluid percussion, the weight-drop or the blast wave model [41]. The impact of the injury in these 168 
models can be assessed both in terms of tissue damage and in terms of neurological impairment, using 169 
various behavioural tests. 170 
The primary injury in TBI is a direct consequence of the impact of such forces on the brain. The damage 171 
created during the primary phase leads to a cascade of processes which amplify the injury - this 172 
constitutes the secondary injury phase. This phase is characterised by mitochondrial dysfunction and 173 
energy deficit, oxidative stress, cell death, neuroinflammation and may or may not be accompanied 174 
by hypoxia or ischaemia [42-44]. The depletion in energy stores and the collapse in ionic gradients 175 
lead to an overflow of the excitatory amino acids glutamate and aspartate and a massive influx of 176 
calcium. One of the consequences of the increased intracellular calcium levels is the activation of 177 
phospholipases. This is a superfamily of hydrolase enzymes, divided into groups and subgroups based 178 
on their specific patterns of cleavage; these enzymes can modify the composition of cellular 179 
membranes, by cleaving PL and releasing free fatty acids and diacylglycerols [45, 46]. One of the most 180 
well studied enzymes in this family is phospholipase A2 (PLA2), which is specific for the sn-2 position of 181 
the glycerol phosphate backbone of PL. The released free fatty acids, such as ARA (an omega-6 fatty 182 
acid) and DHA (an omega-3 fatty acid) can be further metabolised into eicosanoids and docosanoids, 183 
which have powerful modulatory effects on the inflammatory processes triggered by the injury. 184 
Shohami et al. [47] were the first to report changes in PLA2 activity in a TBI model, i.e. closed head 185 
injury in rats. At 15 minutes after trauma, a 75% increase in PLA2 activity was found at the injury 186 
epicenter and at 4 hours, the whole contused brain hemisphere showed elevated PLA2 activity. At the 187 
injury site, PLA2 activity was still 245% of control values at 24 hours after injury. A significant 188 
correlation was found between the elevation in PLA2 activity and the levels of the proinflammatory 189 
eicosanoid prostaglandin E2 (PGE2) in the injured hemisphere. The elevation in PGE2 was abolished 190 
when animals were pre-treated with a PLA2 inhibitor. These results showed that increase in brain 191 
phospholipase activity is a very early event following neurotrauma, and that this mechanism is 192 
involved in the degradation of PL, and the subsequent increased production of fatty acid-derived lipid 193 
mediators, which have intrinsic biological effects and contribute to the pathophysiology of TBI. The 194 
three decades since these first observations were reported have seen a steady accumulation of studies 195 
on lipid changes after TBI, in patients and animal models, which will be discussed below. 196 
3. Lipid changes in human traumatic brain injury  197 
3.1. Serum and plasma 198 
3.1.1. Phospholipids 199 
More than four decades ago, Heller and colleagues reported changes in serum PL in 4 patients with 200 
brain injury and subsequent hypoxia [48] . Patients with acute hypoxia had an increase in PL, whereas 201 
a decrease was seen in patients with chronic hypoxia. The study did not analyse specific PL classes. In 202 
2016, a study in adolescent ice hockey players  showed that 55 hours post-concussion, 82% of the 203 
plasma metabolite variance between  players with or without concussion was explained by 10 204 
components, each including 9 metabolites [49]. The first component, accounting for 28.21% of the 205 
variance, consisted solely of PC species.  PC, lysoPC, as well as SM, were also part of the other 206 
components. In the same year, Emmerich et al. reported a detailed lipid analysis of plasma from 207 
soldiers with mild TBI (no further description), incurred several years before the study, i.e. during 208 
military service in 2008-2010 [50]. Significant decreases in plasma levels of PC (-19%), lysoPC (-24%), 209 
PE (-26%), lysoPE (-24%), PI (-30%) and SM (-17%) were detected, compared to the levels in control 210 
soldiers. Changes were more marked in soldiers who had also developed post-traumatic stress 211 
disorder. Further analysis of the various lipid species within these classes, showed that the decreases 212 
were seen across saturated-, monounsaturated-, and polyunsaturated fatty acid-containing species. 213 
The study also assessed the impact of isoforms of the apolipoprotein E (ApoE) on these changes. ApoE 214 
is a protein involved in lipid metabolism and transport, and the ApoE gene has three alleles: ApoE2, 215 
ApoE3 and ApoE4. Some differences were noted as a function of the ApoE4 genotype. Thus, ApoE4-216 
negative individuals with mild TBI showed significant decreases in monounsaturated fatty acid-217 
containing lysoPC, whereas ApoE4 positive individuals showed no difference compared to controls. 218 
Similar results were seen for saturated-, monounsaturated-, and polyunsaturated fatty acid-219 
containing PE species. In individuals with mild TBI, the ratio of ARA to DHA was also significantly 220 
decreased in PE. When data was stratified for the ApoE4 genotype, the non-carriers had significantly 221 
lower PI than the controls, and ApoE4 carriers had significantly higher lysoPC levels than the controls, 222 
whereas no difference was detected for non-carriers. Ether PL (in which the glycerol backbone has an 223 
ether or vinyl-ether bond at the sn-1 position) levels showed similar patterns of change. Ether PE was 224 
reduced by 25% in mild TBI, whereas no difference could be seen in ether PC. The ApoE4 genotype 225 
also influenced the ether PE, with significantly lower ether PE in ApoE4 non-carriers compared to 226 
carriers, which was also seen for etherPC. This trend was also seen for etherPC species. In a 227 
subsequent analysis, the same group also found no effect of mild TBI on PS plasma levels in soldiers 228 
[51]. The degree of saturation of PS was not changed by mild TBI and no overall effect of the ApoE4 229 
gene was detected. However, PS 38:4 was increased in the ApoE4 non-carrier mild TBI group 230 
compared to ApoE4 non-carrier controls. Using plasma metabolomics, a 6-metabolite panel was 231 
characterized in a cohort of collegiate athletes,  discriminating concussed athletes from age-, sex- and 232 
sports-matched controls within 6 hours, as well as at 2, 3, and 7 days post-injury [52]. The panel 233 
consisted of five lipids, including increased PE P-16:0/20:4, and lysoPC 20:4/0:0, and decreased PE 234 
16:0/22:6, and was validated in an independent, clinical TBI cohort. 235 
3.1.2. Cholesterol 236 
In active duty soldiers, there was no effect of mild TBI on total cholesterol levels or its degree of 237 
unsaturation in plasma [51]. However, the ApoE4 status had an effect. Cholesterol esters of chain 238 
length 20 were significantly higher in plasma in non-carriers after mild TBI compared with control non-239 
carriers.  240 
3.1.3. Free fatty acids 241 
The early report from Heller and colleagues indicated an initial loss of triglycerides and esterified fatty 242 
acids, which corresponded with an increase in free fatty acids [48]. As part of the TBICARE project, 243 
Orešič and colleagues identified the fatty acids 8:0 and 10:0 as upregulated metabolites in the serum 244 
of patients with moderate and severe TBI, within 12 hours of the injury [53]. Both remained elevated 245 
during the first week after TBI. Metabolites in patients with mild TBI followed the same pattern, 246 
however the upregulation was not as pronounced. Furthermore, elevated levels were associated with 247 
poor outcome in these patients, based on the Glasgow Outcome Scale Extended. The 6-metabolite 248 
mild TBI (concussion) panel described by Fiandaca and colleagues also included two fatty acids, 249 
increased 18:0 and decreased oxidised 16:0 [52]. Thomas and colleagues found a positive correlation 250 
between serum metabolite cluster 4 (fatty acids, e.g. ARA) and positive MRI findings in the right 251 
caudate, left lateral ventricle, right lateral orbital gyrus, right middle frontal gyrus and left middle 252 
occipital gyrus in TBI patients [54]. Furthermore, amongst others, serum linoleic acid levels were 253 
indicative of a positive MRI finding.  254 
3.1.4. Cardiolipin 255 
To our knowledge, cardiolipin has not been measured in human plasma after TBI. However, 256 
Anthonymuthu and colleagues have measured nine brain specific cardiolipins in the plasma of patients 257 
with cardiac arrest, within 6 hours of resuscitation [40]. A combination of three of these cardiolipin 258 
species (70:3, 72:5, and 78:11) correlated well with three clinical measures of neurological injury (Full 259 
Outline of UnResponsiveness score, GCS, Pittsburgh Cardiac Arrest Category), with higher values in 260 
patients with poor neurological or functional outcome, and predicted poor discharge status. 261 
Cardiolipin (70:5) on its own, with a cut off of 0.93 pmol/mL, was 83% sensitive and 90% specific in 262 
predicting neurological outcome, and thus might be a suitable biomarker for brain injury in this 263 
context.  264 
3.2. Cerebrospinal fluid 265 
3.2.1. Phospholipids 266 
In 2003, Kay and colleagues measured PL in the lipoprotein fraction of ventricular CSF pooled from 27 267 
patients with severe TBI (GCS<8 within 24 hours of admission) [55]. Comparison with 6 pooled lumbar 268 
CSF samples from 150 controls (patients with suspected neurological disease), showed a significant 269 
increase in PL (0.29 ± 0.09 µM vs. 0.44 µM) after TBI. Pasvogel and colleagues measured PL changes 270 
over 6 days in the CSF of 10 patients with TBI, with a range of GCS from 3 to 11 at admission [56]. 271 
Levels of PE and PC were above normal ranges on day 1-5, and PS and lysoPC were elevated on day 1-272 
6, indicating a disruption of cell membranes in the CNS after TBI. The group further analysed the data 273 
stratified for patients who survived (6/10) and who died [57]. All PL levels were elevated above normal 274 
CSF levels, and all levels apart from lysoPC on day 3 and SM on day 1, were higher in patients who 275 
died, than in those who survived. PE, PC and SM levels were only slightly higher in patients who 276 
survived than in control patients, whereas levels of PS and lysoPC were also elevated in surviving 277 
patients. A second increase in PE, PC, PS, and SM was seen on day 4 (last measurement before death), 278 
potentially indicating secondary injury. 279 
3.2.2. Cholesterol 280 
In a study assessing cholesterol in the CSF of patients with TBI in the acute phase (exact time 281 
unspecified), a pooled sample of 27 severe TBI patients showed a significant 5-fold increase in non-282 
esterified cholesterol in the lipoprotein fraction of ventricular CSF compared to controls [55]. 283 
3.2.3. Free fatty acids 284 
A study measuring free fatty acid levels in CSF after TBI, showed significantly higher levels of myristic 285 
acid, palmitic acid, oleic acid, linoleic acid, ARA and DHA in 15 patients within 48 hours of the insult, 286 
compared to control patients without TBI [58]. In general, free fatty acids were significantly elevated 287 
at 24 and 48 hours after injury and returned towards control levels at 96 hours post-injury. 288 
Furthermore, higher CSF levels of total polyunsaturated fatty acids (linoleic acid, ARA and DHA 289 
combined) as well as myristic acid, palmitic acid and ARA individually, one week after TBI, were 290 
associated with a worse outcome at discharge, defined as a Glasgow Outcome Score of less than 4, 291 
which indicates severe disability or death. Similarly, the same group found significantly higher levels 292 
of the same fatty acids in CSF within 24 hours in patients with subarachnoid haemorrhage (mainly 293 
from ruptured aneurysms) [59], indicating that this pattern is not specific for TBI. Medium-chain fatty 294 
acids, including 8:0 and 10:0, which were upregulated in the serum of TBI patients, were also 295 
detectable in high concentrations in the brain microdialysates from the patients [53].  296 
Free fatty acids increase when PL are degraded. Another end-product of PL degradation is glycerol, 297 
and several studies have measured glycerol in microdialysis samples after TBI [60-62]. Significantly 298 
higher glycerol levels were seen in TBI patients with unfavourable prognosis [61], and in the first 72 299 
hours in TBI patients who died [62]. Furthermore, a peak interstitial glycerol level above 150 µmol/L 300 
had a 100% positive predictive value for an unfavourable outcome, therefore indicating that glycerol 301 
levels correlate with the severity of brain damage [60]. 302 
3.3. Brain tissue 303 
3.3.1. Cardiolipin 304 
Two-dimensional liquid chromatography mass spectrometry analysis of brain tissue from the right 305 
temporal lobe from a patient with severe TBI in the acute stage revealed numerous oxidised 306 
cardiolipins in the penumbra of the contused brain tissue, but no oxidation products of PC or PE [63]. 307 
In contusional brain tissue from severe TBI patients, increased mitophagy has been reported, along 308 
with a decreased mitochondrial to genomic DNA ratio [64]. Animal experiments confirmed increased 309 
mitochondrial autophagy early after CCI [64], and studies in primary cortical neurons indicate that 310 
mitophagy is mediated via the translocation of cardiolipin to the outer mitochondrial membrane [65]. 311 
Therefore, it could be speculated that cardiolipin also mediates mitophagy in human TBI.  312 
4. Lipid changes in experimental traumatic brain injury  313 
4.1. Serum and plasma 314 
4.1.1. Phospholipids 315 
Several experimental TBI studies have reported alterations in plasma PL. Three months after CCI, 316 
6 months old male C57BL/6 mice had overall lower PC, PE and PI levels in plasma [66]. The decrease 317 
in PI was significant and equally distributed between saturated-, monounsaturated-, and 318 
polyunsaturated species. PC and PE only showed significant decreases in monounsaturated species. 319 
Additionally, the DHA to ARA ratio was significantly lower within the PE species. Similar results were 320 
reported by the same group using a closed head injury mouse model, to simulate mild TBI [67], and 321 
over a longer timeline, i.e. at 3, 12 and 24 months post-injury. Levels of PC, lysoPC, PE, lysoPE, and PI 322 
were significantly decreased compared to their own 24 hours post-injury values. This decrease was 323 
injury specific and was greater than the effect of normal ageing. No major changes were seen in 324 
plasma PL after mild TBI at the acute time point (24 hours) vs. controls, whereas significant changes 325 
occurred in the chronic phase. Relative to control mice, plasma levels of PC, lysoPC,, PE, lysoPE and PI 326 
were lower in TBI mice at all chronic time points, with significantly lower levels of PC, PE and PI at 3, 327 
12 and 24 months, lower lysoPC and lysoPE at 3 and 24 months, and lower SM at 24 months only. This 328 
is consistent with reported lower plasma PL in soldiers at a chronic time point after mild TBI [50]. 329 
Overall, results indicated a decrease in PL in the injury phase from 24 hours to 3 months, followed by 330 
a recovery phase to 6 months, and PLs remained overall lower in TBI mice than control mice up to 24 331 
months [67]. The analysis showed that the decreases in PL were evenly distributed between saturated-, 332 
monounsaturated-, and polyunsaturated fatty acids at 3 and 24 months for PC and lysoPC. In contrast, 333 
at 3 months only saturated and polyunsaturated fatty acid-containing PE decreased, and only 334 
saturated and monounsaturated lysoPE species decreased. At 12 months post-injury, levels of 335 
saturated and polyunsaturated PC species were decreased, and in PE and PI only polyunsaturated 336 
species decreased, whereas only monounsaturated species were affected in lysoPE. Twenty-four 337 
months after injury, polyunsaturated PE, lysoPE and PI were decreased, and additionally 338 
monounsaturated lysoPE species decreased. Apart from a significant increase in saturated PE species, 339 
no other PL was affected in the acute phase (24 hours). EtherPC, ether lysoPC, and ether lysoPE were 340 
not different in plasma from TBI animals compared to control animals. However, ether PE was 341 
significantly higher at 24 hours, but significantly lower at 3, 12 and 24 months post-injury in TBI 342 
animals. In general, DHA-containing PL species were decreased after injury, and only etherPC-343 
containing DHA was significantly increased at 24 hours post-injury. At 12 months post-injury, the 344 
majority of DHA-containing PL species were significantly decreased. A similar pattern was seen for 345 
ARA-containing PL species. Overall, this experimental closed head TBI model led to changes similar to 346 
those seen in soldiers with chronic mild TBI.  347 
Hogan and colleagues used untargeted lipidomics and identified a panel of 26 serum lipids that 348 
discriminated between rats with TBI (CCI of the lateral frontoparietal cortex) and control rats with 85% 349 
accuracy [68] at a subacute time, i.e. day 3 and 7 post-injury. Of these lipids, 7 PL (PE 20:4/16:0, 350 
18:2/18:0, 18:0/22:4; PC 20:2/18:0, 16:0/16:0, 18:2/16:0, 18:2/22:1; SM d18:1/22:1; lysoPC 20:2) 351 
were decreased relatively to controls, whereas PS 16:0/20:4 and oxidised lysoPC 18:2 were increased. 352 
All PL, apart from SM, were not significantly different between day 3 and day 7 post-injury. Using a 353 
metabolomics approach, Bahado-Singh and colleagues were able to clearly discriminate closed head 354 
TBI mouse serum samples from control serum samples, based on decreased levels of PC 34:4 and 355 
methionine sulfoxide in the acute phase (4 and 24 hours post-injury) [69]. A 6-component serum 356 
metabolomic panel including SM 18:0 and 18:1 could be used to differentiate early (4 hours) from late 357 
(24 hours post-injury) serum samples, with higher levels in the latter. Plasma PC was not altered 1 358 
hour after lateral fluid percussion in rats, although changes in brain PC were identified [70]. In a pig 359 
TBI model, serum PL metabolism was altered 24 hours post-CCI, but no longer at 7 days [71]. 360 
Sheth and colleagues used a targeted lipid profiling approach to detect changes in rat plasma 361 
sphingolipids [72]. Sphingolipids, mostly SM, increased after CCI. The highest increase was seen in two 362 
SM species; SM 37:1 was significantly increased at 4, 24 and 48 hours, and SM 38:8 was significantly 363 
increased at 24 and 48 hours after TBI. Both returned to normal by 7 days after injury. The increase in 364 
SM was correlated with the lesion volume. Another group investigating SM changes used a blast injury 365 
model of TBI. Four days after mild to moderate blast trauma in mice, SM 22:0, 24:0 and 22:1 were 366 
significantly reduced in plasma compared to their level in control mice [73]. This was accompanied by 367 
a decrease in the precursor dihydro SM 22:0 and 24:0. In contrast, dihydro SM 16:0 was increased 368 
significantly, and a non-significant increase in SM 16:0 was also recorded.  369 
4.1.2. Cholesterol  370 
The 26 lipid panel reported by Hogan and collaborators (see above), differentiating control animals 371 
from rats with TBI, also included cholesterol sulphate, which was significantly reduced in serum after 372 
TBI compared to control animals in the first week after injury [68]. 373 
4.1.3. Free fatty acids 374 
Hogan et al. showed that the free fatty acid 18:0 was significantly more abundant in rat TBI samples 375 
[68]. The release of free fatty acids after focal cold injury was also studied in cats [74]. When no 376 
subsequent cerebral ischaemia developed, plasma levels at 5-7 hours post-injury were similar to levels 377 
before the injury. In animals with a malignant increase in intracranial pressure and subsequent 378 
cerebral ischaemia, plasma levels of 16:0, 18:0, 18:1, 18:2 were significantly increased. In CSF, most 379 
free fatty acids were too low to measure prior to injury. In contrast, almost all fatty acids were higher 380 
in oedema fluid 5-7 hours after injury than in the control CSF. However, they were below the levels in 381 
plasma, with the exception of the omega-6 fatty acid ARA, which was higher in the interstitially drained 382 
oedema fluid.  383 
4.1.4. Cardiolipin 384 
In naïve rat plasma, cardiolipins make up less than 0.001% of PL [38]. After CCI injury in postnatal day 385 
(PND) 17 rats, the phospholipidome was significantly different between naïve and TBI groups, at 4 and 386 
24 hours. Cardiolipins were mainly responsible for the differences, and a time-dependent enrichment 387 
in brain specific cardiolipins was noted. The increase in these brain specific cardiolipins at 24 hours 388 
post-injury correlated significantly with the decrease in these species in the injured cortex. Increased 389 
cardiolipins in plasma included cardiolipin 70:3 and cardiolipin 72:5 [38]. Both these cardiolipins were 390 
also increased in the plasma of cardiac arrest patients with neurological injuries [40], as described 391 
above.  392 
4.2. Brain tissue 393 
4.2.1. Phospholipids 394 
4.2.1.1. Single TBI 395 
Four and 24 hours after fluid percussion injury, rats had significantly lower PL levels in the perilesional 396 
area [75]. A slight decrease was already seen 10 minutes after injury. After a single CCI in juvenile 397 
(PND17) rats, a significant increase in lysoPC was found 3 hours post-CCI in the lesioned cortex [76]. 398 
In a subsequent study, a 2- and 5- fold increase in lysoPC, and a 1.7- and 5-fold increase in lysoPE were 399 
shown in the pericontusional cortex at 4 and 24 hours post-injury, respectively [38]. In both studies, 400 
PL did not change significantly at these time points. Similarly, concussion induced by an impact 401 
acceleration weight drop model, produced no significant changes in brain PC content in the acute and 402 
subacute period (2, 6, 24, 48 and 120 hours post-injury) [77]. However, 1 hour after lateral fluid 403 
percussion injury, 1H NMR metabolomics identified a significant decrease in PC and glyceroPC of 23% 404 
and 19% in the cortex and hippocampus of adult rats, respectively [70]. Twenty-four hours after 405 
cryogenic injury, PL containing ARA and DHA were significantly reduced in the injured hemisphere of 406 
rats [78]. Chitturi and colleagues noted a significant increase in PC and PL biosynthesis in the injured 407 
hemisphere of rats (PND31) at 72 hours post-lateral fluid percussion [79].  Bayir and colleagues found 408 
no changes in SM in the acute phase (3 hours post-injury) of TBI in rats [76]. In contrast to this, 409 
significantly elevated levels of SM were shown in the lesioned hemisphere of mice in the subacute 410 
phase, 2 and 7 days after CCI [80]. In particular, SM species containing 14:0, 16:0, 24:0 and 24:1 were 411 
increased, with increases in SM 14:0 and 16:0 already seen at 24 hours. The precursor 412 
dihydrosphingosine was also significantly increased at 1, 2 and 7 days post-injury. One and 3 days after 413 
CCI, the metabolic profile of TBI rats and control rats in the hippocampus was significantly different 414 
[81]. Although the identified biomarker panel did not include PL, the mechanistic pathway analysis 415 
identified proteins involved in PL metabolism as well as fatty acid degradation.  Abdullah and 416 
colleagues investigated brain PL changes at a chronic time point (3 months after injury) [66]. 417 
Additionally to the changes in plasma PL levels described in the previous section, PC, SM, and PE were 418 
significantly increased (+28%, +37%, +32%, respectively) in the hippocampus, but decreased (-34%, -419 
25%, -31%, respectively) in the cerebellum. In the cortex, PC (-7%) and PE (-18%) were significantly 420 
decreased. In contrast to PI plasma levels, no changes were seen in tissue PI levels. Increases in the 421 
hippocampus were mediated by significant increases in PC saturated and monounsaturated species, 422 
monounsaturated species in PE, and saturated species in PI. In the cortex, significant decreases in 423 
polyunsaturated PC species, and across all PE species, were seen. Cerebellum analysis showed 424 
significantly decreased PC (all species) and monounsaturated PE species. The DHA to ARA ratio was 425 
also altered by TBI. Decreases in this ratio were seen in PC and PE in the hippocampus and the cortex, 426 
and in PI in the cortex. An increase in the DHA to ARA ratio was seen in the cerebellum in PE and in 427 
the hippocampus in PI. EtherPC increased significantly in the hippocampus and decreased significantly 428 
in the cerebellum, whereas the only change in ether PE was a decrease in the cortex.  429 
Bayir and colleagues investigated oxidative modifications in PL after CCI in the juvenile PND17 rat 430 
model [76]. Three hours post-injury, no oxidation of PL was detected, but at 24 hours after injury, PS 431 
was markedly oxidised in the ipsilateral cortex, especially PS species containing DHA. PE, PC, and PI 432 
were slightly oxidised at this time point. This indicates a specific PL species oxidation after TBI, since 433 
oxidation did not follow the relative abundance of PL species. These results were confirmed in a later 434 
study with a similar setup. No change in oxidised PC and PE occurred 3 hours after CCI in juvenile rats 435 
[63].  436 
4.2.1.2. Repetitive TBI 437 
Ojo and colleagues used a repetitive injury model (5 hits over 9 days) in adult C57BL/6 mice [82]. This 438 
resulted in an increase in total cortical PC at 24 hours and 12 months. Total PI significantly decreased 439 
at 3 and increased at 12 months. LysoPE was significantly increased at 24 hours, 3 and 12 months post-440 
injury. The increases in PC at 24 hours and 12 months were seen amongst all levels of unsaturation. 441 
Changes in PI were mediated through significant decreases in polyunsaturated fatty acid-containing 442 
species at 3 months and increases in polyunsaturated fatty acid-containing species at 12 months. ARA 443 
and DHA-containing PC were increased at 24 hours and 12 months, whereas ARA-containing PI were 444 
decreased at 3 months post-injury. Additionally, an increase in total ether PC was shown at 24 hours 445 
and 12 months. In the hippocampus, total PE, PC, SM significantly increased at 24 hours, 6, and 12 446 
months compared to sham mice. PI increased at 24 hours and 12 months. LysoPE increased at 3, 6, 12 447 
months, however lysoPC only increased at 24 hours post-injury. The increases at 24 hours were 448 
distributed equally amongst saturated-, monounsaturated-, and polyunsaturated fatty acid-449 
containing species. Six months after injury, the increase was evenly distributed amongst PE, whereas 450 
only polyunsaturated PC and monounsaturated SM increased. At 12 months post-injury, saturated-, 451 
monounsaturated-, and polyunsaturated PE species increased, whereas within PC, only 452 
monounsaturated and polyunsaturated species increased, and only saturated and monounsaturated 453 
SM species increased. Significant increases in hippocampal ARA-containing PC, PE, and PI were shown 454 
at 24 hours and 12 months. ARA-containing lysoPC increased 24 hours after the last injury. DHA-455 
containing species increased in PC at 24 hours and 12 months, in PE at 24 hours, 6 and 12 months, in 456 
PI at 12 months and in lysoPC 24 hours after the last injury. Ether PE increased at 24 hours, 6, and 12 457 
months, while ether PC only increased 6 months after the last injury. Muza and colleagues also used 458 
a repetitive mild TBI model with 3 CCI per week, over one month [83]. They demonstrated an ApoE 459 
genotype specific effect on PL. Overall, ApoE4-positive mice had significantly higher levels of SM and 460 
PC compared to ApoE3-positive mice; and TBI showed an injury effect in ApoE4-positive mice, with 461 
significantly higher levels of SM (10%) and PC compared to sham operated ApoE4-positive mice. The 462 
increase was seen across saturated-, monounsaturated-, and polyunsaturated PC species. 463 
4.2.1.3. Imaging Studies 464 
Mass spectrometry imaging offers the advantage of displaying regional differences in PL with high 465 
spatial resolution, compared to tissue analysis on brain homogenates. In a rat CCI model, Roux and 466 
colleagues showed that low mass SM, which is normally detected in the ventricular region, was 467 
detected in the injury area 3 days after injury [84]. Intermediate mass SM decreased in the region of 468 
injury at day 1 and 3, but this change was not significant. Overall SM decreased in grey matter at 1 day 469 
post-injury, but increased at day 3 and 7. Ceramide (several species), a breakdown product of SM, 470 
showed higher levels at the injured site between day 1 and 3, followed by a drop on day 7. PE 16:0/22:6 471 
and PE 18:0/22:6 decreased significantly in the injured area at day 3 post-injury. Similarly, PC showed 472 
decreases at 24 hours post-injury, and PC and PI showed decreases at day 3, followed by increases at 473 
day 7. DAG, a product of hydrolysis of PL by phospholipase C, was increased at 3 days, but the 474 
increased levels were attenuated by day 7. Han and colleagues showed that the CCI lesion and 475 
perilesional area 3 days after injury could be distinguished from an uninjured area in the contralateral 476 
cortex using principal component analysis [85]. Part of the discriminating lipid profile was an 477 
upregulation in PC 16:1/16:0 and a downregulation of PE 28:5, PS 18:0/22:6 and PI 38:4. Li and 478 
colleagues found a downregulation of PI in the peripheral region of a TBI injury in rats 3 days post-479 
injury [86]. In juvenile PND17 rats, PI m/z 883.5 and 885.5 were both significantly decreased at the 480 
point of impact 3 hours post-injury and additionally, m/z 885.5 was significantly decreased in the 481 
hippocampus and m/z 883.5 in the thalamus [87]. No changes were noted in the adjacent cortical 482 
region. 483 
Mallah and colleagues used a three dimensional matrix-assisted laser desorption/ionization-mass 484 
spectrometry imaging (MALDI-MSI) approach to study the dynamics of lipid changes after CCI in the 485 
rat cortex, and found specific lipid profiles in the uninjured cortex, the lesion interior and the lesion 486 
exterior, 3 days post-injury [88]. They showed that PE 38:1/PC35:1 was highly expressed in the 487 
uninjured cortex but was absent in the lesion, whereas PC 38:7 and PC 38:4 were both highly 488 
expressed in the lesion but not in the contralateral cortex. Furthermore, PC 42:9 and m/z 723.508 489 
were elevated at the injured site.  490 
Gou and colleagues specifically monitored changes in DHA-containing lipids after TBI in adult rats, in 491 
the fluid percussion injury model [89]. Three days after injury, DHA and lysoPE 22:6 were significantly 492 
increased in the injury area, but PE P-18:0/22:6 (the plasmalogen form), PE 18:0/22:6, and PS 493 
18:0/22:6 were significantly decreased. DHA was also significantly increased at 1 day post-injury at the 494 
injury site and then decreased gradually, but stayed significantly higher than in controls. LysoPE 22:6 495 
was increased at day 1 and further increased until day 3, and returned to normal afterwards. 496 
Lysophosphatidylglycerol 22:6 levels were similar to controls over the first 3 days and increased 497 
significantly on day 5 and day 7 post-injury in the lesion area. PE P-18:0/22:6 was significantly 498 
decreased in the injured area from day 1 and stayed significantly lower for the 7 days post-injury. PE 499 
18:0/22:6 and PS 18:0/22:6 were significantly decreased from day 1, and increased afterwards until 500 
day 7 post-injury, when they were still significantly lower than in controls.  501 
4.2.2. Cholesterol 502 
Adult rats receiving a cryogenic brain injury had an 18% decrease in cholesterol in the lesioned 503 
hemisphere 24 hours post-injury [78]. Similarly, a significant decrease in cholesterol was seen in rats 504 
at 10 minutes, 4 hours and 24 hours after fluid percussion injury in the perilesional area [75]. The study 505 
by Roux and collaborators showed a strong signal for cholesterol throughout the rat adult brain, and 506 
it was decreased at 3 and 7 days post-CCI in the injured area [84]. Interestingly, this was followed by 507 
an increase in cholesterol in the corpus callosum, dentate gyrus and the internal capsule after 3 days. 508 
Cholesterol esters were not detected in the brain in control animals, but increased significantly in the 509 
injured area at 3 and 7 days post-injury, the time points at which the decline in the cholesterol signal 510 
was seen.  511 
4.2.3. Free fatty acids 512 
Rats subjected to fluid percussion injury had significantly higher free fatty acid levels (+119%) in the 513 
hippocampus 5 minutes after injury [90]. At 20 minutes post-injury, levels were still elevated, but this 514 
was no longer statistically significant. A similar pattern was seen for 18:0 and ARA, which both 515 
increased significantly at 5 minutes (+180%) and stayed elevated at 20 minutes. No change in 16:0 and 516 
18:1 was seen. In another fluid percussion study, all free fatty acids (16:0, 18:0, 18:1, 18:3, ARA and 517 
DHA) were significantly higher in the fluid percussion-injured area in rats at 4 and 24 hours post-injury 518 
[75], and 18:0 and ARA were already significantly increased 10 minutes after the injury.  519 
Dhillon and colleagues subjected rats to CCI and assessed free fatty acids at 30 minutes, 2.5 hours and 520 
24 hours after the injury [91]. All free fatty acids (16:0, 18:0, 18:1, ARA) were significantly higher in 521 
the injury site compared to control animals at all time points. In the region adjacent to the injury site, 522 
only 18:0 and ARA were significantly elevated at all time points. In the ipsilateral hippocampus, ARA 523 
was significantly increased at 30 minutes and 2.5 hours after the injury and 18:0 was significantly 524 
increased 2.5 hours after the injury. In the contralateral cortex, only ARA at 2.5 hours post-injury was 525 
elevated. Similarly, total free fatty acids, as well as 16:0, 18:0, 18:1, and ARA increased significantly in 526 
the injury area in the cortex of male rats 30 minutes after the injury [92]. At 6 hours, total free fatty 527 
acids, as well as 16:0, 18:0, and ARA were still significantly elevated. In the region adjacent to the 528 
injury, total free fatty acids as well as 16:0 and 18:0 were also significantly elevated 30 minutes after 529 
the injury, and remained so at 6 hours after the injury, including ARA levels. In the ipsilateral 530 
hippocampus, total free fatty acids as well as 16:0, 18:0,18:1 and ARA were significantly elevated 30 531 
minutes post-injury, and at 6 hours all fatty acids returned to control levels. In the contralateral cortex, 532 
no change in free fatty acids was seen at any time point. Homayoun and colleagues investigated 533 
changes in free fatty acids in rats subjected to CCI, at a subacute (4 days) and chronic (35 days) time 534 
point [93]. At both time points, significantly higher free fatty acids were detected in the frontal right 535 
cortex (injury site), compared to sham operated animals, with much higher levels at 4 days post-injury. 536 
Free fatty acids were also significantly elevated in the contralateral frontal left cortex; however, these 537 
increases were less than in the injured cortex. In other regions (occipital cortex, hippocampus, 538 
cerebellum and brainstem), total free fatty acids did not change after TBI. Individual free fatty acids 539 
(16:0, 18:0, 18:1, ARA, and DHA) were all significantly increased at 4 days post-injury in the injured 540 
cortex, whereas on the contralateral side all free fatty acids were increased, but only the increase in 541 
DHA was significant. Additionally, increases in ARA and DHA were significant in the occipital right 542 
cortex. These changes remained stable at 35 days post-injury for 18:0, 18:1 and ARA in the frontal 543 
right cortex, and for ARA in the occipital right cortex. Furthermore, at 35 days post-injury, 18:0, 18:1 544 
and ARA were significantly increased in the frontal left cortex. Lipid metabolism was significantly 545 
increased in the injured hemisphere of rats (PND31) compared to sham TBI and TBI uninjured 546 
hemispheres at 72 hours post-fluid percussion [79]. Furthermore, the uninjured hemisphere also 547 
showed a significant increase in lipid metabolism, compared to sham TBI. In a pig TBI model, ARA 548 
metabolism was altered 7 days after CCI in the grey and white matter of the injured hemisphere [71]. 549 
Glycerolipid metabolism was also affected. 550 
Anthonymuthu and colleagues investigated the time course of fatty acid oxidation after CCI in juvenile 551 
rats (PND17) [94]. The amount of non-enzymatic oxidised lipids was similar in TBI and in naïve animals, 552 
therefore, the majority of oxidised lipids were generated by enzymatic oxidation. One hour after TBI, 553 
16 octadecanoids, 89 eicosanoids, 96 docosanoids, and 20 oxidised ultra-long chain polyunsaturated 554 
fatty acids were significantly increased. Of these, 3 octadecanoids, 47 eicosanoids, 55 docosanoids, 555 
and 10 ultra-long chain polyunsaturated fatty acids remained elevated at 4 hours, and 14 eicosanoids, 556 
4 docosanoids, and 1 ultra-long chain polyunsaturated fatty acid remained elevated at 24 hours post 557 
injury. Of the elevated docosanoids, 8 were specialised pro-resolving mediators. Overall, both pro- 558 
and anti-inflammatory oxidised free fatty acids were produced after TBI and were elevated at 1 hour 559 
after injury, and at 4 hours both decreased, but were still above naïve levels. Pro-inflammatory 560 
mediators returned to normal at 24 hours post-injury, while anti-inflammatory mediators remained 561 
elevated.  562 
4.2.4. Cardiolipin 563 
TBI leads to an increased energy demand in the brain, which results in increased mitochondrial 564 
respiration and subsequent reactive oxygen species production. This oxidative stress can damage 565 
mitochondria, which in turn will translocate cardiolipin to the outer mitochondria membrane resulting 566 
in autophagy, as early as one hour after CCI, in juvenile (PND17) rats [64]. This elimination of damaged 567 
mitochondria precedes cardiolipin-induced apoptosis and is neuroprotective after TBI.  568 
Using MALDI-MSI, Li and colleagues reported a down-regulation of cardiolipins in the perilesional area 569 
of a CCI injury in adult rats [86]. Another imaging study confirmed these results in PND17 rats [87]. 570 
Three hours after injury, cardiolipin levels were significantly decreased in the injured region, in the 571 
hippocampus and in the thalamus. However, no changes were noted in the adjacent cortical region. 572 
Similarly, in PND17 rats, cardiolipin level decreased significantly in the pericontusional cortex at 4 573 
hours (-96%) and 24 hours (-89%) after CCI injury, with a uniform decrease across all cardiolipin species 574 
[38]. Chao and colleagues also reported significant losses in cardiolipins rich in polyunsaturated fatty 575 
acids in the cortical contusional zone at 1, 4, and 24 hours post-CCI in PND17 rats, with the highest 576 
decrease at 4 hours [95]. Due to their unsaturation, polyunsaturated fatty acids are prone to oxidation. 577 
Indeed, imaging mass spectrometry identified significant losses in polyunsaturated cardiolipins in the 578 
ipsilateral contusional cortex at 3 hours post-injury, and additionally cardiolipin decreased in the CA3 579 
region of the hippocampus and thalamus on the ipsilateral side [39]. Levels of oxidised cardiolipins 580 
peaked at 1 hour post-injury (>3.5-fold) in the study by Chao and colleagues, and elevated levels were 581 
still noted at 4 and 24 hours post-injury [95]. These lower oxidised cardiolipin levels at later time points 582 
were mainly due to decreases in oxidised cardiolipins containing polyunsaturated fatty acids. 583 
Monolysocardiolipins slightly increased at 1 hour post-injury and further increased at 4 and 24 hours. 584 
A steady increase in monolysocardiolipins with less than seven double bonds was noted at later time 585 
points, likely reflecting hydrolysis of cardiolipins. It was noted that the early oxidation of cardiolipin 586 
was specific and not just caused by the high amount of cardiolipin containing DHA [76]. The PND17 587 
rat CCI model showed oxidation of polyunsaturated cardiolipins at 3 hours post-injury, whereas other 588 
PL were not oxidised. Therefore, cardiolipin was specifically oxidised early on after TBI, and 589 
additionally, in the TBI group, apoptotic markers were increased at 24 hours post-injury. Oxidised 590 
cardiolipin has been described to be essential for the release of proapoptotic factors [96]. Similarly, Ji 591 
and colleagues reported oxidation of cardiolipins in the whole brain after CCI, using two-dimensional 592 
liquid chromatography mass spectrometry [63]. They identified that the number of oxidised 593 
cardiolipins increased from 10 in naïve brains to 166, 30 minutes after TBI. The oxidation was linked 594 
to cell death and lesion volume, and inhibition of oxidation by applying a brain-permeable 595 
mitochondria-targeted electron scavenger led to improved outcomes.  596 
5. Discussion 597 
The studies reviewed here show a complex pattern of changes in various lipids, in blood, in CSF and in 598 
brain tissue. Key changes in major species in blood and CSF are summarized in Figure 2. The timeline 599 
of the various studies spans a period starting in the first hours after injury and up to several months 600 
or years after injury. Some lipid species show a monophasic change (decrease or increase as a function 601 
of time post-trauma), whereas other species show a biphasic change. There are several questions 602 
which are raised by these observations, around the lipid dynamics in the peripheral vs. the central 603 
compartment, how the changes in the two compartments could be linked and what avenues they 604 
open to improve diagnosis and prognosis in TBI. 605 
a) What underlies the dynamic alterations in lipids, from the acute to the chronic period? It could 606 
be hypothesized that changes in the acute period (less than 24 hours after injury), both in 607 
blood and brain tissue, reflect the initial damage to tissue, and the primary injury-induced 608 
rapid demise of various structural components, including membrane lipids. The decrease in 609 
tissue PL is a consequence of the activation of enzymes such as the phospholipases which 610 
increase their activity in less than an hour following injury [47, 97]. However, as time 611 
progresses towards the subacute phase, the injury element is likely to be complemented by 612 
the emergence of a pro-repair response, and gradually the balance of processes becomes 613 
more heavily weighted towards neurorepair and regeneration. Bahado-Singh et al. [69] 614 
identified lipids as part of a complex serum metabolomic panel, in a closed TBI mouse model, 615 
and showed that certain lipids such as PC 34:4 are part of a metabolomic set that differentiates 616 
TBI from control animals, whereas SM 18:0 and 18:1 were specifically part of a set that 617 
reflected the evolution of the injury from 4 hours to 24 hours. In a study on serum 618 
neuroproteomics in rat CCI, Kobeissy and collaborators [98], also illustrated these shifts in 619 
panel composition between the acute (1 day) and subacute period (7 days) post-injury, with 620 
proteins involved in neurorepair, axon growth and neuroregeneration being upregulated at 621 
the subacute time after injury. 622 
 623 
 624 
Figure 2: Summary of dynamic changes in lipids from various lipid classes in human blood 625 
(plasma, serum) and human CSF in TBI clinical studies, and blood (plasma, serum) in 626 
experimental models of TBI. Increased values vs. respective controls are represented above the 627 
line, and decreased values below the line. PC (phosphatidylcholine), PE (phosphatidyl-628 
ethanolamine), lysoPC (lysophosphatidylcholine), lysoPE (lysophosphatidylethanolamine); SM 629 
(sphingomyelin), CL (cardiolipin), PI (phosphatidylinositol), PS (phosphatidylserine), OA (oleic acid), 630 
DHA (docosahexaenoic acid), ARA (arachidonic acid), PA (palmitic acid), SA (stearic acid), OC 631 
(octanoic acid), DEC (decanoic acid), PL (total phospholipids), CHOL (cholesterol), GLY (glycerol). 632 
b) How are changes in the peripheral compartment linked to the changes detected in the injured 633 
brain tissue? There are several possible mechanisms responsible for the transfer of substances 634 
from the central compartment into the peripheral compartment: mechanical BBB disruption 635 
[99], passive efflux from brain/CSF [100], and also glymphatic transport [101]. The disruption 636 
of the BBB is maximal within a few hours post-trauma [102, 103], therefore it is very likely that 637 
in the acute period the transfer is mainly a consequence of the BBB being damaged by injury. 638 
In support of this hypothesis, Orešič  et al. [53] showed that there is a similarity between the 639 
changes seen in serum and in the brain microdialysate from TBI patients, in the acute phase. 640 
However, it is also interesting to note that Glushakova et al. [104] showed that some of the 641 
changes in BBB can be protracted, and may be directly linked to pathological processes such 642 
as white matter injury post-trauma, which unfold over a longer time. 643 
c) What is the correlation between the changes seen in specific lipids and neurological outcome 644 
post-TBI? Only a few studies have so far explored this aspect. Thus, Pilitsis et al. [58] clearly 645 
showed that the high levels of fatty acids in the CSF post-TBI, correlated with poorer outcome. 646 
Orešič  et al. [53] also reported that high levels of medium-chain fatty acids, linked to tissue 647 
energy metabolism disruption, are correlated with poorer outcome. Yi et al. [105] explored 648 
potential markers of TBI-induced cognitive impairment in patients with moderate to severe 649 
TBI; their study provided evidence that changes in certain fatty acids, i.e. palmitic acid 650 
(decrease), linoleic acid and ARA (increase) are linked to TBI with poor cognitive outcome, as 651 
compared to TBI devoid of this complication.  652 
d) How specific are lipid changes reported in traumatic injury vs. an injury of the brain of vascular 653 
origin, such as stroke? Pilitsis et al. [106] have reported similar observations on high fatty acid 654 
(such as ARA and DHA) levels in CSF following stroke, with higher levels being predictors of 655 
poorer outcome. Furthermore, Liu et al. [107] have shown that high levels of lysoPC 18:2 in 656 
serum could have prognostic value for the development of post-stroke cognitive impairment. 657 
Stroke activates phospholipases such as cPLA2 [108], and this could explain the PL changes 658 
similar to those reported in TBI. Therefore, it appears that stroke also leads to changes in 659 
specific lipid species, in the central or peripheral compartment. 660 
e) Can the changes seen suggest new therapeutic solutions in TBI, targeting lipid disruption? The 661 
decline in certain lipids, such as DHA, in brain tissue, suggests that supplementation with this 662 
fatty acid may have beneficial effects after brain injury. Interestingly, in athletes who are at 663 
risk of repeated brain concussion during a football season, the treatment with moderate doses 664 
of DHA may have protective effects [109]. There is also evidence that providing animals after 665 
a CCI injury with a multi-nutrient containing PL biosynthetic precursors, significantly improves 666 
outcome [110].  667 
a) Are there specific lipids which appear to be the most sensitive biomarkers of TBI? The data so 668 
far has not enabled the identification of a uniquely sensitive and specific lipid biomarker (or 669 
biomarker panel) for TBI, applicable across the whole spectrum of this condition. However, 670 
there are interesting observations in recent studies on specific CNS lipids such as brain-specific 671 
cardiolipin, associated with mitochondrial damage [38], or oxidized PL species, e.g. 672 
hydroperoxy-arachidonoyl- and adrenoyl-PE, associated with the ferroptosis process 673 
triggered by TBI [111, 112]. Furthermore, there is still limited information on the levels of 674 
eicosanoids and docosanoids after TBI, in human studies and animal models. New insights are 675 
likely to be generated in future studies focused on these lipid mediator species. 676 
6. Conclusion 677 
The concerted effort in the biomarker field over the last decade has led to identification of a variety 678 
of biomarkers of TBI, reflecting neuronal or astrocytic injury, BBB disruption or the immune response 679 
triggered by neurotrauma [21, 113]. Biomarker measurements in blood are less invasive, therefore 680 
likely to be more easily implemented in the clinic. There are already strong candidates such as 681 
neurofilament L, the protein tau (total t-tau or the phosphorylated form p-tau), glial fibrillary acidic 682 
protein (GFAP), ubiquitin C-terminal hydrolase L1 (UCHL1), S100 calcium-binding protein B (S100B) 683 
and spectrin breakdown products (SBDP). A recent study showed that in the first 2 weeks after TBI, 684 
GFAP and NFL levels added the most independent information to improve prediction of outcome [114]. 685 
It is likely that the field of TBI biomarkers will evolve towards use of various panels of biomarkers, 686 
suited to specific questions, for example, the panel used to predict within the first 24 hours whether 687 
a mild TBI patient requires a scan will be different from that used to predict over the first 3-7 days the 688 
outcome after a severe TBI - as recently discussed by Gan and collaborators [21]. Therefore, future 689 
efforts in lipidomics may follow a similar path, and focus on specific severities and stages of the injury 690 
in order to better personalize the management of this complex condition. There is still an open 691 
question whether TBI studies (including biomarker research) in rodents, with a much lower white 692 
matter to grey matter ratio than humans [115, 116], are the most informative. Furthermore, before 693 
moving from research evidence to clinical practice in TBI, there are still unresolved issues in the field, 694 
linked to the design, analysis and reporting of biomarker studies, and the analytical rigour and 695 
reproducibility of the data [117, 118]. It is to be hoped that the combination of different types of 696 
biomarkers, including specific lipids, and reflecting different cellular origins and pathophysiological 697 
processes, will become a valuable tool for improved patient stratification in future TBI clinical studies. 698 
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